ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In a second study of 131 patients not achieving MMR after 2 years of TKI therapy, Bidikian and colleagues observed that the 10-year CML-specific survival rate was similar (95%) among patients with BCR::ABL1 transcripts (IS) > 0.1%–1% and >1%–10% [46].